Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ROBERT J BUYNAK

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1508977984
CMS profile
340544
Location
VALPARAISO, IN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$2,804.68

27 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Travel and Lodging $1,807.28 10
Food and Beverage $997.40 17

By paying entity

PY2024 · entire year · sorted by reported total

Paying entityAmountRecords
ModernaTX, Inc. $1,924.95 17
AstraZeneca Pharmaceuticals LP $729.73 8
Boehringer Ingelheim Pharmaceuticals, Inc. $150.00 2

Page 1 of 1; records 1–27 of 27 matching records. This page contains 27 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ROBERT J BUYNAK

NPI 1508977984 · CMS profile ID 340544

Allopathic & Osteopathic Physicians / Internal Medicine

VALPARAISO, IN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–27 of 27 matching records. This page contains 27 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1508977984?year=2024&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ROBERT J BUYNAK, NPI 1508977984, CMS profile ID 340544. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–27 of 27 matching records. This page contains 27 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1508977984?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). ROBERT J BUYNAK, NPI 1508977984, CMS profile ID 340544. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–27 of 27 matching records. This page contains 27 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1508977984?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
ROBERT J BUYNAK, NPI 1508977984, CMS profile ID 340544, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–27 of 27 matching records. This page contains 27 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1508977984?year=2024&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

27 matching records · $2,804.68 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 27 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–27 of 27.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
ModernaTX, Inc. $240.0009/14/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152558606 CMS
ModernaTX, Inc. $318.9609/14/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152558608 CMS
ModernaTX, Inc. $177.0109/14/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152558610 CMS
ModernaTX, Inc. $265.5309/14/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152558612 CMS
ModernaTX, Inc. $120.0009/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152558614 CMS
ModernaTX, Inc. $45.0009/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152558616 CMS
ModernaTX, Inc. $30.0009/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152558618 CMS
ModernaTX, Inc. $81.0009/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152558620 CMS
ModernaTX, Inc. $30.0009/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152558622 CMS
AstraZeneca Pharmaceuticals LP $24.4409/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104288350 CMS
AstraZeneca Pharmaceuticals LP $27.9409/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104385089 CMS
AstraZeneca Pharmaceuticals LP $27.9409/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104473474 CMS
AstraZeneca Pharmaceuticals LP $81.0009/06/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104543482 CMS
AstraZeneca Pharmaceuticals LP $97.7809/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105367592 CMS
AstraZeneca Pharmaceuticals LP $71.2409/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105375956 CMS
AstraZeneca Pharmaceuticals LP $292.3309/06/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105442631 CMS
AstraZeneca Pharmaceuticals LP $107.0609/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105540731 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $35.0001/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1118039628 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $115.0001/19/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1118039630 CMS
ModernaTX, Inc. $150.0001/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152558536 CMS
ModernaTX, Inc. $217.3501/04/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152558538 CMS
ModernaTX, Inc. $50.0001/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152558540 CMS
ModernaTX, Inc. $25.0001/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152558542 CMS
ModernaTX, Inc. $50.0001/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152558544 CMS
ModernaTX, Inc. $25.0001/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152558600 CMS
ModernaTX, Inc. $50.0501/04/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152558602 CMS
ModernaTX, Inc. $50.0501/04/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152558604 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $5,627.38 35
PY2022 $1,515.77 9
PY2023 $2,547.31 21
PY2024 $2,804.68 27
PY2025 $2,542.53 14

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $3,038,550.53 603
PY2024 Principal investigator $5,031,915.33 601
PY2023 Recipient $906.71 2
PY2023 Principal investigator $4,138,599.32 2,384
PY2022 Recipient $3,104.59 10
PY2022 Principal investigator $5,204,363.35 1,133
PY2021 Principal investigator $3,348,948.64 610
PY2020 Recipient $1,489.26 13
PY2020 Principal investigator $1,938,354.41 292
PY2019 Recipient $658.79 10
PY2019 Principal investigator $1,439,149.33 218

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

228 records in PY2019

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 AstraZeneca Pharmaceuticals LP $934.29 12/31/2019 Non-covered Recipient Entity
Buynak Clinical Research
A Long Term Outcomes Study to Assess STatin Residual Risk Reduction with EpaNova in HiGh Cardiovascular Risk PatienTs with Hypertriglyceridemia No dispute reported 06/30/2026 684975909
Principal investigator 1 AstraZeneca UK Limited $3,916.43 12/31/2019 Non-covered Recipient Entity
Buynak Clinical Research
A Long Term Outcomes Study to Assess STatin Residual Risk Reduction with EpaNova in HiGh Cardiovascular Risk PatienTs with Hypertriglyceridemia No dispute reported 06/30/2026 684999247
Principal investigator 1 Novo Nordisk AS $72.00 12/27/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 706670045
Principal investigator 1 Novo Nordisk AS $9.00 12/27/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 706670047
Principal investigator 1 Novo Nordisk AS $16.25 12/23/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 706670081
Principal investigator 1 Novo Nordisk AS $16.25 12/23/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 706670083
Principal investigator 1 Novo Nordisk AS $16.25 12/23/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 706670085
Principal investigator 1 Novo Nordisk AS $16.25 12/23/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 706670087
Principal investigator 1 Novo Nordisk AS $16.25 12/23/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 706670089
Principal investigator 1 Novo Nordisk AS $16.25 12/23/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 706670091
Principal investigator 1 Novo Nordisk AS $16.25 12/23/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 706670093
Principal investigator 1 Novo Nordisk AS $16.25 12/23/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 706670095
Principal investigator 1 Novo Nordisk AS $16.25 12/23/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 706670097
Principal investigator 1 Novo Nordisk AS $16.25 12/23/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 706670099
Principal investigator 1 Novo Nordisk AS $16.25 12/23/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 706670101
Principal investigator 1 Eisai Inc. $27,503.10 12/21/2019 Non-covered Recipient Entity
Buynak Clinical Research, P.C.
A 52 Week Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Belviq XR in Conjunction With Lifestyle Modification for Weight Loss in Obese Adolescents, Age 12 to 17 Years No dispute reported 06/30/2026 705597421
Principal investigator 1 Novo Nordisk AS $486.00 12/19/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 692450135
Principal investigator 1 Novo Nordisk AS $74.97 12/19/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 706670049
Principal investigator 1 Gilead Sciences, Inc. $8,427.00 12/18/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH, P.C.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Evaluating the Efficacy and Safety of Selonsertib in Subjects with Moderate to Advanced Diabetic Kidney Disease No dispute reported 06/30/2026 676496161
Principal investigator 1 Kowa Research Institute, Inc. $1,973.70 12/16/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH PC
K-877-302 No dispute reported 06/30/2026 629128219
Principal investigator 1 Novo Nordisk AS $24.99 12/16/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 706670065
Principal investigator 1 SANOFI US SERVICES INC. $1,412.00 12/16/2019 Non-covered Recipient Entity
Buynak Clinical Research PC
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes, Cardiovascular Risk Factors and Moderately Impaired Renal Function No dispute reported 06/30/2026 691598107
Principal investigator 1 SANOFI US SERVICES INC. $860.00 12/11/2019 Non-covered Recipient Entity
Valley Research Trials
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes, Cardiovascular Risk Factors and Moderately Impaired Renal Function No dispute reported 06/30/2026 691598123
Principal investigator 1 Novo Nordisk AS $117.78 12/05/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 706670051
Principal investigator 1 Novo Nordisk AS $3.90 12/05/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 706670053
Principal investigator 1 Kowa Research Institute, Inc. $13,695.30 12/03/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH PC
K-877-302 No dispute reported 06/30/2026 629128221
Principal investigator 1 Novo Nordisk AS $5,697.00 12/03/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 692450133
Principal investigator 1 Novo Nordisk AS $54.00 12/03/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 706670067
Principal investigator 1 Novo Nordisk AS $13.50 12/03/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 706670069
Principal investigator 1 Novo Nordisk AS $9.75 12/03/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 706670071
Principal investigator 1 Novo Nordisk AS $90.00 12/03/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 706670073
Principal investigator 1 Novo Nordisk AS $13.50 12/03/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 706670075
Principal investigator 1 Novo Nordisk AS $74.97 12/03/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 706670077
Principal investigator 1 Novo Nordisk AS $7.95 12/03/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 706670079
Principal investigator 1 Novo Nordisk AS $7.99 11/27/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 706670103
Principal investigator 1 Novo Nordisk AS $32.50 11/27/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 706670105
Principal investigator 1 Novo Nordisk AS $32.50 11/27/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 706670107
Principal investigator 1 Novo Nordisk AS $32.50 11/27/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 706670109
Principal investigator 1 Novo Nordisk AS $32.50 11/27/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 706670111
Principal investigator 1 Novo Nordisk AS $32.50 11/27/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 706670113
Principal investigator 1 Novo Nordisk AS $32.50 11/27/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 706670115
Principal investigator 1 Novo Nordisk AS $32.50 11/27/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 706670117
Principal investigator 1 Novo Nordisk AS $32.50 11/27/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 706670119
Principal investigator 1 Novo Nordisk AS $32.50 11/27/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 706670121
Principal investigator 1 Novo Nordisk AS $32.50 11/27/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 706670123
Principal investigator 1 Novo Nordisk AS $32.50 11/27/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 706670125
Principal investigator 1 Novo Nordisk AS $56.90 11/27/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 706670127
Principal investigator 1 Novo Nordisk AS $56.90 11/27/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 706670129
Principal investigator 1 Novo Nordisk AS $56.90 11/27/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 706670131
Principal investigator 1 Novo Nordisk AS $56.90 11/27/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 706670133
Principal investigator 1 Novo Nordisk AS $56.90 11/27/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 706670135
Principal investigator 1 Novo Nordisk AS $56.90 11/27/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 706670137
Principal investigator 1 Novo Nordisk AS $56.90 11/27/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 706670139
Principal investigator 1 Novo Nordisk AS $56.90 11/27/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 706670141
Principal investigator 1 Novo Nordisk AS $56.90 11/27/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 706670143
Principal investigator 1 Novo Nordisk AS $56.90 11/27/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 706670145
Principal investigator 1 Novo Nordisk AS $56.90 11/27/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 706670147
Principal investigator 1 Novo Nordisk AS $56.90 11/27/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 706670149
Principal investigator 1 Novo Nordisk AS $56.90 11/27/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 706670151
Principal investigator 1 Novo Nordisk AS $56.90 11/27/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 706670153
Principal investigator 1 Novo Nordisk AS $56.90 11/27/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 706670155
Principal investigator 1 Novo Nordisk AS $56.90 11/27/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 706670157
Principal investigator 1 Novo Nordisk AS $56.90 11/27/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 706670159
Principal investigator 1 Novo Nordisk AS $56.90 11/27/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 706670161
Principal investigator 1 Novo Nordisk AS $56.90 11/27/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 706670163
Principal investigator 1 Novo Nordisk AS $56.90 11/27/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 706670165
Principal investigator 1 Novo Nordisk AS $56.90 11/27/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 706670167
Principal investigator 1 Novo Nordisk AS $25.50 11/27/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 706670169
Principal investigator 1 Novo Nordisk AS $25.50 11/27/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 706670171
Principal investigator 1 Novo Nordisk AS $25.50 11/27/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 706670173
Principal investigator 1 Novo Nordisk AS $25.50 11/27/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 706670175
Principal investigator 1 Novo Nordisk AS $25.50 11/27/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 706670177
Principal investigator 1 Novo Nordisk AS $25.50 11/27/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 706670179
Principal investigator 1 Novo Nordisk AS $25.50 11/27/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 706670181
Principal investigator 1 Novo Nordisk AS $25.50 11/27/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 706670183
Principal investigator 1 Novo Nordisk AS $25.50 11/27/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 706670185
Principal investigator 1 Novo Nordisk AS $25.50 11/27/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 706670187
Principal investigator 1 Novo Nordisk AS $25.50 11/27/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 706670189
Principal investigator 1 Novo Nordisk AS $25.50 11/27/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 706670191
Principal investigator 1 Novo Nordisk AS $25.50 11/27/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 706670193
Principal investigator 1 Novo Nordisk AS $25.50 11/27/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 706670195
Principal investigator 1 Novo Nordisk AS $25.50 11/27/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 706670197
Principal investigator 1 Novo Nordisk AS $25.50 11/27/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 706670199
Principal investigator 1 Novo Nordisk AS $25.50 11/27/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 706670201
Principal investigator 1 Novo Nordisk AS $25.50 11/27/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 706670203
Principal investigator 1 Novo Nordisk AS $25.50 11/27/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 706670205
Principal investigator 1 Novo Nordisk AS $25.50 11/27/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 706670207
Principal investigator 1 Novo Nordisk AS $25.50 11/27/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 706670209
Principal investigator 1 Novo Nordisk AS $25.50 11/27/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
EX9536-4388 No dispute reported 06/30/2026 706670211
Principal investigator 1 Eisai Inc. $33,633.00 11/21/2019 Non-covered Recipient Entity
Buynak Clinical Research, P.C.
A 52 Week Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Belviq XR in Conjunction With Lifestyle Modification for Weight Loss in Obese Adolescents, Age 12 to 17 Years No dispute reported 06/30/2026 705597419
Principal investigator 1 SANOFI US SERVICES INC. $7,251.00 11/18/2019 Non-covered Recipient Entity
Buynak Clinical Research PC
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes, Cardiovascular Risk Factors and Moderately Impaired Renal Function No dispute reported 06/30/2026 691598415
Principal investigator 1 PFIZER INC. $5,879.84 11/12/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH PC
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 26WEEK MULTICENTER STUDY WITH A 78WEEK EXTENSION TO EVALUATE THE EFFICACY AND SAFETY OF ERTUGLIFLOZIN IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS AND INADEQUATE GLYCEMIC CONTROL ON METFORMIN MO No dispute reported 06/30/2026 671666029
Principal investigator 1 SANOFI US SERVICES INC. $1,449.00 11/12/2019 Non-covered Recipient Entity
Valley Research Trials
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes, Cardiovascular Risk Factors and Moderately Impaired Renal Function No dispute reported 06/30/2026 691598375
Principal investigator 1 Novo Nordisk AS $6,967.08 10/29/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 692450125
Principal investigator 1 Kowa Research Institute, Inc. $9,698.40 10/25/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH PC
K-877-302 No dispute reported 06/30/2026 629128217
Principal investigator 1 Kowa Research Institute, Inc. $3,255.60 10/24/2019 Non-covered Recipient Entity
Buynak Clinical Research, P.C.
K-877-301 No dispute reported 06/30/2026 629123467
Principal investigator 1 Kowa Research Institute, Inc. $250.00 10/24/2019 Non-covered Recipient Entity
Buynak Clinical Research, P.C.
K-877-301 No dispute reported 06/30/2026 629123469
Principal investigator 1 Kowa Research Institute, Inc. $2,902.80 10/24/2019 Non-covered Recipient Entity
Buynak Clinical Research, P.C.
K-877-303 No dispute reported 06/30/2026 629130923
Principal investigator 1 PFIZER INC. $33,467.36 10/22/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH PC
A PHASE 3 RANDOMIZED DOUBLEBLIND ACTIVECONTROLLED MULTICENTER STUDY OF THE LONGTERM SAFETY AND EFFICACY OF SUBCUTANEOUS ADMINISTRATION OF TANEZUMAB IN SUBJECTS WITH OSTEOARTHRITIS OF THE HIP OR KNEE No dispute reported 06/30/2026 671666031
Principal investigator 1 Eisai Inc. $24,408.00 10/21/2019 Non-covered Recipient Entity
Buynak Clinical Research, P.C.
A 52 Week Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Belviq XR in Conjunction With Lifestyle Modification for Weight Loss in Obese Adolescents, Age 12 to 17 Years No dispute reported 06/30/2026 705597417
Principal investigator 1 SANOFI US SERVICES INC. $6,008.00 10/21/2019 Non-covered Recipient Entity
Buynak Clinical Research PC
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes, Cardiovascular Risk Factors and Moderately Impaired Renal Function No dispute reported 06/30/2026 691589325
Principal investigator 1 SANOFI US SERVICES INC. $13,095.00 10/21/2019 Non-covered Recipient Entity
Buynak Clinical Research PC
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes, Cardiovascular Risk Factors and Moderately Impaired Renal Function No dispute reported 06/30/2026 691594599
Principal investigator 1 SANOFI US SERVICES INC. $1,155.00 10/21/2019 Non-covered Recipient Entity
Valley Research Trials
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes, Cardiovascular Risk Factors and Moderately Impaired Renal Function No dispute reported 06/30/2026 691595411
Principal investigator 1 AstraZeneca Pharmaceuticals LP $5,886.00 10/18/2019 Non-covered Recipient Entity
Buynak Clinical Research
A Long Term Outcomes Study to Assess STatin Residual Risk Reduction with EpaNova in HiGh Cardiovascular Risk PatienTs with Hypertriglyceridemia No dispute reported 06/30/2026 684975899
Principal investigator 1 Gilead Sciences, Inc. $6,500.00 10/14/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH, P.C.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Evaluating the Efficacy and Safety of Selonsertib in Subjects with Moderate to Advanced Diabetic Kidney Disease No dispute reported 06/30/2026 676496159
Principal investigator 1 Eisai Inc. $7,000.00 10/07/2019 Non-covered Recipient Entity
Buynak Clinical Research, P.C.
A 52 Week Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Belviq XR in Conjunction With Lifestyle Modification for Weight Loss in Obese Adolescents, Age 12 to 17 Years No dispute reported 06/30/2026 705597415
Principal investigator 1 SANOFI US SERVICES INC. $1,596.00 10/07/2019 Non-covered Recipient Entity
Buynak Clinical Research PC
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes, Cardiovascular Risk Factors and Moderately Impaired Renal Function No dispute reported 06/30/2026 691591293
Principal investigator 1 SANOFI US SERVICES INC. $7,863.00 10/02/2019 Non-covered Recipient Entity
Buynak Clinical Research PC
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes, Cardiovascular Risk Factors and Moderately Impaired Renal Function No dispute reported 06/30/2026 691585643
Principal investigator 1 SANOFI US SERVICES INC. $4,420.00 10/02/2019 Non-covered Recipient Entity
Valley Research Trials
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes, Cardiovascular Risk Factors and Moderately Impaired Renal Function No dispute reported 06/30/2026 691587995
Principal investigator 1 Kowa Research Institute, Inc. $10,292.40 10/01/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH PC
K-877-302 No dispute reported 06/30/2026 629128215
Principal investigator 1 Novo Nordisk AS $27.25 10/01/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 706670055
Principal investigator 1 Novo Nordisk AS $15.15 10/01/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 706670057
Principal investigator 1 Novo Nordisk AS $39.95 10/01/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 706670059
Principal investigator 1 Novo Nordisk AS $180.00 10/01/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 706670061
Principal investigator 1 Novo Nordisk AS $14.95 10/01/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 706670063
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $15,572.20 10/01/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
A Randomized, Double-Blind, Placebo-Controlled, Phase 4, Relapse Prevention Study Evaluating the Efficacy and Safety of Vortioxetine 5, 10 and 20 mg in Adults With Major Depressive Disorder No dispute reported 06/30/2026 686160411
Principal investigator 1 Novo Nordisk AS $9,639.00 09/26/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 692450131
Recipient Gilead Sciences, Inc. $29.00 09/14/2019 Covered Recipient Physician A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Evaluating the Efficacy and Safety of Selonsertib in Subjects with Moderate to Advanced Diabetic Kidney Disease No dispute reported 06/30/2026 676473159
Recipient Gilead Sciences, Inc. $17.23 09/13/2019 Covered Recipient Physician A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Evaluating the Efficacy and Safety of Selonsertib in Subjects with Moderate to Advanced Diabetic Kidney Disease No dispute reported 06/30/2026 676473145
Recipient Gilead Sciences, Inc. $18.31 09/13/2019 Covered Recipient Physician A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Evaluating the Efficacy and Safety of Selonsertib in Subjects with Moderate to Advanced Diabetic Kidney Disease No dispute reported 06/30/2026 676473147
Recipient Gilead Sciences, Inc. $41.39 09/13/2019 Covered Recipient Physician A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Evaluating the Efficacy and Safety of Selonsertib in Subjects with Moderate to Advanced Diabetic Kidney Disease No dispute reported 06/30/2026 676473151
Recipient Gilead Sciences, Inc. $47.90 09/13/2019 Covered Recipient Physician A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Evaluating the Efficacy and Safety of Selonsertib in Subjects with Moderate to Advanced Diabetic Kidney Disease No dispute reported 06/30/2026 676473155
Recipient Gilead Sciences, Inc. $47.90 09/13/2019 Covered Recipient Physician A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Evaluating the Efficacy and Safety of Selonsertib in Subjects with Moderate to Advanced Diabetic Kidney Disease No dispute reported 06/30/2026 676473157
Recipient Gilead Sciences, Inc. $23.65 09/12/2019 Covered Recipient Physician A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Evaluating the Efficacy and Safety of Selonsertib in Subjects with Moderate to Advanced Diabetic Kidney Disease No dispute reported 06/30/2026 676473133
Recipient Gilead Sciences, Inc. $29.00 09/12/2019 Covered Recipient Physician A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Evaluating the Efficacy and Safety of Selonsertib in Subjects with Moderate to Advanced Diabetic Kidney Disease No dispute reported 06/30/2026 676473139
Recipient Gilead Sciences, Inc. $108.06 09/12/2019 Covered Recipient Physician A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Evaluating the Efficacy and Safety of Selonsertib in Subjects with Moderate to Advanced Diabetic Kidney Disease No dispute reported 06/30/2026 676473141
Recipient Gilead Sciences, Inc. $296.35 09/10/2019 Covered Recipient Physician A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Evaluating the Efficacy and Safety of Selonsertib in Subjects with Moderate to Advanced Diabetic Kidney Disease No dispute reported 06/30/2026 676473125
Principal investigator 1 Novo Nordisk AS $2,308.00 09/10/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 692450127
Principal investigator 1 Novo Nordisk AS $1,270.00 09/10/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 692450129
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,500.00 09/03/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
A Randomized, Double-Blind, Placebo-Controlled, Phase 4, Relapse Prevention Study Evaluating the Efficacy and Safety of Vortioxetine 5, 10 and 20 mg in Adults With Major Depressive Disorder No dispute reported 06/30/2026 686160317
Principal investigator 1 Janssen Research & Development, LLC $13,446.00 08/30/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH PC
A Randomized, Double-blind Placebo-controlled, Parallel-group, Multicenter, Dose-ranging Study to Evaluate the Safety and Efficacy of JNJ-64565111 in Severely Obese Subjects with Type 2 Diabetes Mellitus No dispute reported 06/30/2026 654244425
Principal investigator 1 Janssen Research & Development, LLC $741.00 08/30/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH PC
A Randomized, Double-blind Placebo-controlled, Parallel-group, Multicenter, Dose-ranging Study to Evaluate the Safety and Efficacy of JNJ-64565111 in Severely Obese Subjects with Type 2 Diabetes Mellitus No dispute reported 06/30/2026 654244427
Principal investigator 1 Janssen Research & Development, LLC $146.25 08/30/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH PC
A Randomized, Double-blind Placebo-controlled, Parallel-group, Multicenter, Dose-ranging Study to Evaluate the Safety and Efficacy of JNJ-64565111 in Severely Obese Subjects with Type 2 Diabetes Mellitus No dispute reported 06/30/2026 654244429
Principal investigator 1 Janssen Research & Development, LLC $9,054.00 08/30/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH PC
A Randomized, Double-blind Placebo-controlled, Parallel-group, Multicenter, Dose-ranging Study to Evaluate the Safety and Efficacy of JNJ-64565111 in Severely Obese Subjects with Type 2 Diabetes Mellitus No dispute reported 06/30/2026 654244431
Principal investigator 1 SANOFI US SERVICES INC. $8,314.00 08/26/2019 Non-covered Recipient Entity
Buynak Clinical Research PC
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes, Cardiovascular Risk Factors and Moderately Impaired Renal Function No dispute reported 06/30/2026 691582193
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $445.52 08/21/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH PC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FASINUMAB IN PATIENTS WITH MODERATE-TO-SEVERE CHRONIC LOW BACK PAIN AND OSTEOARTHRITIS OF THE HIP OR KNEE No dispute reported 06/30/2026 639740159
Principal investigator 1 Novo Nordisk AS $18.00 08/19/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 706670245
Principal investigator 1 Novo Nordisk AS $4.50 08/19/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 706670247
Principal investigator 1 Novo Nordisk AS $3.25 08/19/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 706670249
Principal investigator 1 Novo Nordisk AS $30.00 08/19/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 706670251
Principal investigator 1 Novo Nordisk AS $4.50 08/19/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 706670253
Principal investigator 1 Novo Nordisk AS $24.99 08/19/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 706670255
Principal investigator 1 Novo Nordisk AS $2.65 08/19/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 706670257
Principal investigator 1 Novo Nordisk AS $19.96 08/19/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 706670259
Principal investigator 1 Novo Nordisk AS $19.96 08/19/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 706670261
Principal investigator 1 SANOFI US SERVICES INC. $1,718.00 08/05/2019 Non-covered Recipient Entity
Buynak Clinical Research PC
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes, Cardiovascular Risk Factors and Moderately Impaired Renal Function No dispute reported 06/30/2026 691593903
Principal investigator 1 Novo Nordisk AS $90,812.69 07/30/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN1250-4252 No dispute reported 06/30/2026 692450121
Principal investigator 1 Novo Nordisk AS $1,000.00 07/30/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN1250-4252 No dispute reported 06/30/2026 692450123
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,274.00 07/30/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH PC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FASINUMAB IN PATIENTS WITH MODERATE-TO-SEVERE CHRONIC LOW BACK PAIN AND OSTEOARTHRITIS OF THE HIP OR KNEE No dispute reported 06/30/2026 639740157
Principal investigator 1 SANOFI US SERVICES INC. $9,785.00 07/29/2019 Non-covered Recipient Entity
Buynak Clinical Research PC
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes, Cardiovascular Risk Factors and Moderately Impaired Renal Function No dispute reported 06/30/2026 691581990
Principal investigator 1 PFIZER INC. $1,959.94 07/25/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH PC
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 26WEEK MULTICENTER STUDY WITH A 78WEEK EXTENSION TO EVALUATE THE EFFICACY AND SAFETY OF ERTUGLIFLOZIN IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS AND INADEQUATE GLYCEMIC CONTROL ON METFORMIN MO No dispute reported 06/30/2026 671665267
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,524.62 07/24/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH PC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FASINUMAB IN PATIENTS WITH MODERATE-TO-SEVERE CHRONIC LOW BACK PAIN AND OSTEOARTHRITIS OF THE HIP OR KNEE No dispute reported 06/30/2026 639740155
Principal investigator 1 SANOFI US SERVICES INC. $1,540.00 07/22/2019 Non-covered Recipient Entity
Valley Research Trials
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes, Cardiovascular Risk Factors and Moderately Impaired Renal Function No dispute reported 06/30/2026 691584947
Principal investigator 1 Kowa Research Institute, Inc. $24,102.90 07/18/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH PC
K-877-302 No dispute reported 06/30/2026 629128213
Principal investigator 1 Novo Nordisk AS $36.00 07/16/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 706670213
Principal investigator 1 Novo Nordisk AS $9.00 07/16/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 706670215
Principal investigator 1 Novo Nordisk AS $6.50 07/16/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 706670217
Principal investigator 1 Novo Nordisk AS $60.00 07/16/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 706670219
Principal investigator 1 Novo Nordisk AS $9.00 07/16/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 706670221
Principal investigator 1 Novo Nordisk AS $49.98 07/16/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 706670223
Principal investigator 1 Novo Nordisk AS $5.30 07/16/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 706670225
Principal investigator 1 Novo Nordisk AS $1.08 07/12/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 706670227
Principal investigator 1 Novo Nordisk AS $36.00 07/03/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 706670229
Principal investigator 1 Novo Nordisk AS $9.00 07/03/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 706670231
Principal investigator 1 Novo Nordisk AS $6.50 07/03/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 706670233
Principal investigator 1 Novo Nordisk AS $60.00 07/03/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 706670235
Principal investigator 1 Novo Nordisk AS $9.00 07/03/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 706670237
Principal investigator 1 Novo Nordisk AS $49.98 07/03/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 706670239
Principal investigator 1 Novo Nordisk AS $5.30 07/03/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 706670241
Principal investigator 1 SANOFI US SERVICES INC. $2,130.00 07/02/2019 Non-covered Recipient Entity
Valley Research Trials
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes, Cardiovascular Risk Factors and Moderately Impaired Renal Function No dispute reported 06/30/2026 691582721
Principal investigator 1 SANOFI US SERVICES INC. $5,351.00 07/02/2019 Non-covered Recipient Entity
Buynak Clinical Research PC
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes, Cardiovascular Risk Factors and Moderately Impaired Renal Function No dispute reported 06/30/2026 691585021
Principal investigator 1 Novo Nordisk AS $22.97 06/26/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 706670043
Principal investigator 1 Novo Nordisk AS $4.99 06/25/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 706670263
Principal investigator 1 Novo Nordisk AS $5.36 06/25/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 706670265
Principal investigator 1 Novo Nordisk AS $3.05 06/25/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 706670267
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $270.00 06/21/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
A Randomized, Double-Blind, Placebo-Controlled, Phase 4, Relapse Prevention Study Evaluating the Efficacy and Safety of Vortioxetine 5, 10 and 20 mg in Adults With Major Depressive Disorder No dispute reported 06/30/2026 686160315
Principal investigator 1 Novo Nordisk AS $75.00 06/20/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN9535-4321 No dispute reported 06/30/2026 706670243
Principal investigator 1 PFIZER INC. $52,638.16 06/17/2019 Non-covered Recipient Entity
Buynak Clinical Research PC
A PHASE 3 RANDOMIZED DOUBLE BLIND PLACEBO AND ACTIVECONTROLLED MULTICENTER PARALLELGROUP STUDY OF THE ANALGESIC EFFICACY AND SAFETY OF TANEZUMAB IN ADULT SUBJECTS WITH CHRONIC LOW BACK PAIN No dispute reported 06/30/2026 671622631
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,677.00 06/04/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
A Randomized, Double-Blind, Placebo-Controlled, Phase 4, Relapse Prevention Study Evaluating the Efficacy and Safety of Vortioxetine 5, 10 and 20 mg in Adults With Major Depressive Disorder No dispute reported 06/30/2026 686160321
Principal investigator 1 SANOFI US SERVICES INC. $5,303.00 06/03/2019 Non-covered Recipient Entity
Valley Research Trials
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes, Cardiovascular Risk Factors and Moderately Impaired Renal Function No dispute reported 06/30/2026 691582255
Principal investigator 1 SANOFI US SERVICES INC. $5,303.00 06/03/2019 Non-covered Recipient Entity
Valley Research Trials
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes, Cardiovascular Risk Factors and Moderately Impaired Renal Function No dispute reported 06/30/2026 691592119
Principal investigator 1 SANOFI US SERVICES INC. $10,840.00 05/29/2019 Non-covered Recipient Entity
Buynak Clinical Research PC
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes, Cardiovascular Risk Factors and Moderately Impaired Renal Function No dispute reported 06/30/2026 691605181
Principal investigator 1 SANOFI US SERVICES INC. $4,960.00 05/29/2019 Non-covered Recipient Entity
Buynak Clinical Research PC
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes, Cardiovascular Risk Factors and Moderately Impaired Renal Function No dispute reported 06/30/2026 691605639
Principal investigator 1 Novo Nordisk AS $12,087.12 05/28/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN1218-4113 No dispute reported 06/30/2026 692450109
Principal investigator 1 Novo Nordisk AS $1,000.00 05/28/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN1218-4113 No dispute reported 06/30/2026 692450111
Principal investigator 1 Novo Nordisk AS $3,000.00 05/28/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN1250-4252 No dispute reported 06/30/2026 692450119
Principal investigator 1 Kowa Research Institute, Inc. $8,932.50 05/22/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH PC
K-877-302 No dispute reported 06/30/2026 629128209
Principal investigator 1 Kowa Research Institute, Inc. $963.90 05/16/2019 Non-covered Recipient Entity
Buynak Clinical Research, P.C.
K-877-301 No dispute reported 06/30/2026 629123465
Principal investigator 1 Novo Nordisk AS $402.20 05/07/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN1250-4252 No dispute reported 06/30/2026 692450117
Principal investigator 1 Kowa Research Institute, Inc. $18,905.40 05/06/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH PC
K-877-302 No dispute reported 06/30/2026 629128211
Principal investigator 1 PFIZER INC. $4,119.96 05/02/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH PC
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 26WEEK MULTICENTER STUDY WITH A 78WEEK EXTENSION TO EVALUATE THE EFFICACY AND SAFETY OF ERTUGLIFLOZIN IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS AND INADEQUATE GLYCEMIC CONTROL ON METFORMIN MO No dispute reported 06/30/2026 671631657
Principal investigator 1 PFIZER INC. $15,415.00 04/30/2019 Non-covered Recipient Entity
Buynak Clinical Research PC
A PHASE 3 RANDOMIZED DOUBLE BLIND PLACEBO AND ACTIVECONTROLLED MULTICENTER PARALLELGROUP STUDY OF THE ANALGESIC EFFICACY AND SAFETY OF TANEZUMAB IN ADULT SUBJECTS WITH CHRONIC LOW BACK PAIN No dispute reported 06/30/2026 671622613
Principal investigator 1 Novo Nordisk AS $160.88 04/25/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN1218-4113 No dispute reported 06/30/2026 692450103
Principal investigator 1 Novo Nordisk AS $300.00 04/25/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN1218-4113 No dispute reported 06/30/2026 692450105
Principal investigator 1 Novo Nordisk AS $360.00 04/25/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN1218-4113 No dispute reported 06/30/2026 692450107
Principal investigator 1 Janssen Research & Development, LLC $3,055.00 04/23/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH PC
A Randomized, Double-blind Placebo-controlled, Parallel-group, Multicenter, Dose-ranging Study to Evaluate the Safety and Efficacy of JNJ-64565111 in Severely Obese Subjects with Type 2 Diabetes Mellitus No dispute reported 06/30/2026 654244421
Principal investigator 1 SANOFI US SERVICES INC. $4,533.00 04/22/2019 Non-covered Recipient Entity
Valley Research Trials
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes, Cardi No dispute reported 06/30/2026 691579167
Principal investigator 1 SANOFI US SERVICES INC. $15,325.00 04/22/2019 Non-covered Recipient Entity
Buynak Clinical Research PC
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes, Cardi No dispute reported 06/30/2026 691579173
Principal investigator 1 Novo Nordisk AS $864.00 04/11/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN1250-4252 No dispute reported 06/30/2026 692450113
Principal investigator 1 Novo Nordisk AS $2,160.00 04/11/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN1250-4252 No dispute reported 06/30/2026 692450115
Principal investigator 1 Janssen Research & Development, LLC $2,732.00 04/09/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH PC
A Randomized, Double-blind Placebo-controlled, Parallel-group, Multicenter, Dose-ranging Study to Evaluate the Safety and Efficacy of JNJ-64565111 in Severely Obese Subjects with Type 2 Diabetes Mellitus No dispute reported 06/30/2026 654244423
Principal investigator 1 Amgen Inc. $184.56 04/08/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
GALACTIC-HF No dispute reported 06/30/2026 675783579
Principal investigator 1 PFIZER INC. $2,046.72 04/03/2019 Non-covered Recipient Entity
Buynak Clinical Research PC
A PHASE 3 RANDOMIZED DOUBLEBLIND ACTIVECONTROLLED MULTICENTER STUDY OF THE LONGTERM SAFETY AND EFFICACY OF SUBCUTANEOUS ADMINISTRATION OF TANEZUMAB IN SUBJECTS WITH OSTEOARTHRITIS OF THE HIP OR KNEE No dispute reported 06/30/2026 671622615
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $333.00 03/26/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
A Randomized, Double-Blind, Placebo-Controlled, Phase 4, Relapse Prevention Study Evaluating the Efficacy and Safety of Vortioxetine 5, 10 and 20 mg in Adults With Major Depressive Disorder No dispute reported 06/30/2026 686160323
Principal investigator 1 SANOFI US SERVICES INC. $4,266.00 03/25/2019 Non-covered Recipient Entity
Buynak Clinical Research PC
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes, Cardi No dispute reported 06/30/2026 691573587
Principal investigator 1 SANOFI US SERVICES INC. $8,662.00 03/25/2019 Non-covered Recipient Entity
Valley Research Trials
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes, Cardi No dispute reported 06/30/2026 691573769
Principal investigator 1 Romark Laboratories, LC $106,040.04 03/22/2019 Non-covered Recipient Entity
PharmaSeek, LLC
A Phase III Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Nitazoxanide and Nitazoxanide Plus Oseltamivir in the Treatment of Acute Uncomplicated Influenza No dispute reported 06/30/2026 687330917
Principal investigator 1 Romark Laboratories, LC $526,259.94 03/22/2019 Non-covered Recipient Entity
PharmaSeek, LLC
Efficacy and Safety of Nitazoxanide in the Treatment of Colds Due to Enterovirus/Rhinovirus Infection No dispute reported 06/30/2026 687330935
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,790.10 03/07/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
A Randomized, Double-Blind, Placebo-Controlled, Phase 4, Relapse Prevention Study Evaluating the Efficacy and Safety of Vortioxetine 5, 10 and 20 mg in Adults With Major Depressive Disorder No dispute reported 06/30/2026 686160409
Principal investigator 1 Novo Nordisk AS $5,297.00 03/05/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN1218-4113 No dispute reported 06/30/2026 692450093
Principal investigator 1 Novo Nordisk AS $500.00 03/05/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN1218-4113 No dispute reported 06/30/2026 692450095
Principal investigator 1 Novo Nordisk AS $983.34 03/05/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN1218-4113 No dispute reported 06/30/2026 692450097
Principal investigator 1 Janssen Research & Development, LLC $1,846.00 03/04/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH PC
A Randomized, Double-blind Placebo-controlled, Parallel-group, Multicenter, Dose-ranging Study to Evaluate the Safety and Efficacy of JNJ-64565111 in Severely Obese Subjects with Type 2 Diabetes Mellitus No dispute reported 06/30/2026 654244419
Principal investigator 1 Novo Nordisk AS $488.70 02/21/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN1250-4252 No dispute reported 06/30/2026 692450101
Principal investigator 1 Kowa Research Institute, Inc. $2,389.50 02/14/2019 Non-covered Recipient Entity
Buynak Clinical Research, P.C.
K-877-301 No dispute reported 06/30/2026 629123463
Principal investigator 1 SANOFI US SERVICES INC. $6,421.00 02/11/2019 Non-covered Recipient Entity
Buynak Clinical Research PC
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes, Cardi No dispute reported 06/30/2026 691563387
Principal investigator 1 Kowa Research Institute, Inc. $1,492.20 02/07/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH PC
K-877-302 No dispute reported 06/30/2026 629128207
Principal investigator 1 PFIZER INC. $5,049.92 02/07/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH PC
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 26WEEK MULTICENTER STUDY WITH A 78WEEK EXTENSION TO EVALUATE THE EFFICACY AND SAFETY OF ERTUGLIFLOZIN IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS AND INADEQUATE GLYCEMIC CONTROL ON METFORMIN MO No dispute reported 06/30/2026 671620171
Principal investigator 1 Janssen Research & Development, LLC $9,168.00 02/04/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH PC
A Randomized, Double-blind Placebo-controlled, Parallel-group, Multicenter, Dose-ranging Study to Evaluate the Safety and Efficacy of JNJ-64565111 in Severely Obese Subjects with Type 2 Diabetes Mellitus No dispute reported 06/30/2026 654244417
Principal investigator 1 Amgen Inc. $4,786.00 01/29/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH P C
GALACTIC-HF No dispute reported 06/30/2026 675783581
Principal investigator 1 AstraZeneca Pharmaceuticals LP $47,866.40 01/24/2019 Non-covered Recipient Entity
Buynak Clinical Research
Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 in Subjects With Moderate to Very Severe COPD (Ethos) No dispute reported 06/30/2026 684975905
Principal investigator 1 Novo Nordisk AS $3,269.16 01/24/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN1218-4113 No dispute reported 06/30/2026 692450091
Principal investigator 1 Novo Nordisk AS $24,947.70 01/24/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
NN1250-4252 No dispute reported 06/30/2026 692450099
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,199.60 01/23/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
A Randomized, Double-Blind, Placebo-Controlled, Phase 4, Relapse Prevention Study Evaluating the Efficacy and Safety of Vortioxetine 5, 10 and 20 mg in Adults With Major Depressive Disorder No dispute reported 06/30/2026 686160319
Principal investigator 1 Kowa Research Institute, Inc. $1,455.30 01/21/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH PC
K-877-302 No dispute reported 06/30/2026 629128205
Principal investigator 1 AstraZeneca UK Limited $24,673.50 01/11/2019 Non-covered Recipient Entity
Buynak Clinical Research
A Long Term Outcomes Study to Assess STatin Residual Risk Reduction with EpaNova in HiGh Cardiovascular Risk PatienTs with Hypertriglyceridemia No dispute reported 06/30/2026 684999243
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $234.00 01/02/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
A Randomized, Double-Blind, Placebo-Controlled, Phase 4, Relapse Prevention Study Evaluating the Efficacy and Safety of Vortioxetine 5, 10 and 20 mg in Adults With Major Depressive Disorder No dispute reported 06/30/2026 686160407
Principal investigator 1 Amgen Inc. $1,940.54 01/01/2019 Non-covered Recipient Entity
BUYNAK CLINICAL RESEARCH
GALACTIC-HF No dispute reported 06/30/2026 675783577